Loading clinical trials...
Loading clinical trials...
This study is designed to investigate whether sympathoinhibition with moxonidine could provide added metabolic benefit compared to the second line therapy in the current guidelines.
This is a randomised, double-blind, cross-over study. Participants will be randomly assigned to receive either moxonidine 0.4mg daily or amlodipine 5mg and will later receive the alternate treatment. Comprehensive testing will occur after each 12 week treatment phase and will include assessment of muscle sympathetic nerve activity, gut microbiome analysis and metabolic markers.
Age
25 - 70 years
Sex
ALL
Healthy Volunteers
No
Dobney Hypertension Centre
Perth, Western Australia, Australia
Start Date
June 24, 2015
Primary Completion Date
February 24, 2024
Completion Date
June 24, 2024
Last Updated
September 29, 2022
120
ESTIMATED participants
Moxonidine 0.4 MG
DRUG
Amlodipine 5mg
DRUG
Lead Sponsor
Royal Perth Hospital
Collaborators
NCT01143454
NCT02417740
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions